- Home
- LI vs ABVX Comparison
LI vs ABVX Comparison
Compare LI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LI | ABVX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.9B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LI | ABVX |
|---|---|---|
| Price | $12.04 | $114.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $19.66 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 2.4M | 800.9K |
| Earning Date | 05-28-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.98 | $52.14 |
| Revenue Next Year | $22.72 | $4,132.27 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $69.81 |
| 52 Week High | $26.94 | $148.83 |
Technical Indicators
Market Signals| Indicator | LI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 43.20 |
| Support Level | $12.09 | $107.67 |
| Resistance Level | $12.39 | $129.00 |
| Average True Range (ATR) | 0.28 | 3.63 |
| MACD | -0.04 | -0.48 |
| Stochastic Oscillator | 26.37 | 33.75 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.